Stock Ratings / Health Care / XERS / financials

TRVI (39) BRVE (47) ADRX (52) TRAX (33) ⌘ Pro Terminal →

Xeris Biopharma Holdings Inc. (XERS) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$10.75 +1.03% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Xeris Biopharma Holdings Inc. (XERS) carries a Roarable Rating of C (Hold) with 62/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C • HOLD / WATCH Cap $1.96B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERHOLD / WATCH • C

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE+1.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for XERS)Realized 20D OHLCV Swing Band: ±10.4%

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How XERS Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$28.6M (9.8% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $163.9M

FY24

Rev $203.1M

FY25

Rev $291.8M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$291.8M	52%	8.5%	$554.0K	$28.6M	16%
FY 2024	$203.1M	52%	-16.6%	-$54.8M	-$37.0M	-23%
FY 2023	$163.9M	52%	-26.8%	-$62.3M	-$47.0M	16%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring XERS)

✓Walkthrough of XERS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

XERS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +75.37%▲ ASCENDING CHANNEL

2026-10-30O $10.81H $10.88L $10.52C $10.75VOL 1.55M

RES: $12.23SUP: $8.21SMA50: $9.31SMA200: $7.50

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

XERS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 XERS Butterfly Map → + Track XERS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

48.0%/yr Implied 5Y Growth

vs. +43.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on XERS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for XERS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for XERS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (XERS)

Health Care Rank #168 of 1016 ⚔️ TRVI vs XERS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (XERS vs. TRVI, BRVE, ADRX, TRAX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Xeris Biopharma Holdings Inc. (XERS) ranks #168 by composite RQD confidence (62/100, grade C) and #267 by equity capitalization ($1.96B). Within this direct 5-issuer industry benchmark cohort, XERS leads on earnings valuation at N/A trailing P/E, while XERS leads on capital efficiency and profitability with 16.0% ROIC and — gross margin. XERS currently leads its immediate peer cohort in composite quantitative strength at 62/100 (C).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
XERS ACTIVE Xeris Biopharma Holdings Inc.	C	62/100	—	—	16.0%	+1.03%	$1.96B	Benchmark Subject
TRVI Trevi Therapeutics Inc.	D-	39/100	—	—	-23.7%	+2.15%	$1.97B	/trvi-vs-xers →
BRVE Braveheart Bio Inc.	D	47/100	—	—	—	-2.62%	$1.91B	/brve-vs-xers →
ADRX ADARx Pharmaceuticals Inc.	D+	52/100	—	—	—	-0.56%	$1.91B	/adrx-vs-xers →
TRAX First Tracks Biotherapeutics Inc.	E	33/100	—	—	-35.0%	-1.08%	$1.90B	/trax-vs-xers →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001867096

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Xeris Biopharma Holdings Inc. (XERS) reported GAAP revenue of $291.8M (+43.7% vs. FY2024 revenue of $203.1M , and +78.0% cumulative change since FY2023) , GAAP net income of $554.0K, operating cash flow of $28.6M, and free cash flow of $28.6M (+177.4% YoY). On the balance sheet, XERS closed FY2025 with $383.5M in total assets against $220.3M in total debt (Altman Z-Score: 2.11, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$291.8M	$554.0K	$28.6M	$28.6M	$383.5M	$220.3M
FY2024 (FY)	2024-12-31	$203.1M	-$54.8M	-$37.0M	-$37.0M	$323.1M	$217.0M
FY2023 (FY)	2023-12-31	$163.9M	-$62.3M	-$47.0M	-$47.0M	—	—

3. XERS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is XERS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Xeris Biopharma Holdings Inc. (NASDAQ: XERS) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 62/100 at a spot price of $10.75 (+1.03% 1D, market cap $1.96B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 11/20. Across 1016 tracked Health Care issuers, XERS ranks #168 in composite RQD confidence.

How does XERS compare to TRVI and BRVE in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), XERS carries a Roarable C (62/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 16.0%. By comparison, TRVI (Trevi Therapeutics Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -23.7%, cap $1.97B) and BRVE (Braveheart Bio Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $1.91B). Among the 5-stock peer group, XERS leads on earnings multiple (N/A) while XERS leads on capital efficiency (16.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for XERS?

Per XERS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001867096), Xeris Biopharma Holdings Inc. generated $291.8M in revenue (+43.7% YoY), $554.0K in net income, and $28.6M in free cash flow against $383.5M in total assets and $220.3M in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is XERS trading relative to its 50-day, 200-day, and 52-week technical levels?

XERS last traded at $10.75 (+1.03% on volume of 1,745,572 shares), positioning the stock +15.47% above its 50-day simple moving average ($9.31) and +43.33% above its 200-day simple moving average ($7.50). Across its 52-week range of $5.25 to $11.42, XERS sits at the 89.1% percentile with a 14-day RSI of 60.0 (BULLISH MOMENTUM) and an implied next-earnings move of ±10.4% ($9.63 to $11.87).